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Abstract
Background: Trials of iron chelator regimens have increased the treatment options for cardiac siderosis in beta-
thalassemia major (TM) patients. Treatment effects with improved left ventricular (LV) ejection fraction (EF) have
been observed in patients without overt heart failure, but it is unclear whether these changes are clinically
meaningful.
Methods: This retrospective study of a UK database of TM patients modelled the change in EF between serial
scans measured by cardiovascular magnetic resonance (CMR) to the relative risk (RR) of future development of
heart failure over 1 year. Patients were divided into 2 strata by baseline LVEF of 56-62% (below normal for TM) and
63-70% (lower half of the normal range for TM).
Results: A total of 315 patients with 754 CMR scans were analyzed. A 1% absolute increase in EF from baseline
was associated with a statistically significant reduction in the risk of future development of heart failure for both
the lower EF stratum (EF 56-62%, RR 0.818, p < 0.001) and the higher EF stratum (EF 63-70%, RR 0.893 p = 0.001).
Conclusion: These data show that during treatment with iron chelators for cardiac siderosis, small increases in
LVEF in TM patients are associated with a significantly reduced risk of the development of heart failure. Thus the
iron chelator induced improvements in LVEF of 2.6% to 3.1% that have been observed in randomized controlled
trials, are associated with risk reductions of 25.5% to 46.4% for the development of heart failure over 12 months,
which is clinically meaningful. In cardiac iron overload, heart mitochondrial dysfunction and its relief by iron
chelation may underlie the changes in LV function.
Background
Major advances have been made in the last 10 years in
the understanding and treatment of cardiac siderosis in
beta-thalassaemia major (TM) patients. Those advances
are attributable primarily to the development of a
method for the quantification of myocardial iron based
on magnetic resonance T2* imaging and its worldwide
adoption,[1,2] which has permitted the recognition of
the high prevalence of cardiac siderosis in patients
chronically treated with deferoxamine, [1,3,4]the estab-
lishment of the association of cardiac siderosis with
impaired left ventricular ejection fraction (LVEF) [1,5-7]
the identification of iron-chelation regimes which are
effective in removal of iron from the heart [8-12] and
the reduction in cardiac mortality in populations[13-15].
Studies reporting on the use of iron chelators in treating
transfusional iron overload have raised interesting ques-
tions with regard to cardiac efficacy relating to changes
in the mean LVEF of the TM cohorts under study. Stu-
dies of TM patients in heart failure with severe cardiac
siderosis and depressed LVEF show that combination
treatment with deferiprone and deferoxamine increased
mean absolute cohort LVEF by 14% over 1 year,[10] or
treatment with continuous intravenous deferoxamine
raised LVEF by 11%[16]. Changes in LVEF of this mag-
nitude accompanied with relief of heart failure have
clear clinical benefit. However, in TM patients with
mild to moderate cardiac siderosis, randomized con-
trolled trials of deferiprone monotherapy raised the
mean cohort absolute LVEF by 3.1%,[8] whilst
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absolute LVEF by 2.6%[9]. The clinical meaningfulness
of these statistically significant but smaller improve-
m e n t si nL V E Fi sl e s sc l e a r .W et h e r e f o r es o u g h tt o
determine the clinical significance of changes in LVEF
from a UK database of TM patients by statistical model-
ling of the change in LVEF between serial scans to the
future development of heart failure, which is an impor-
tant clinical endpoint in TM associated with a high
mortality[14,17].
Methods
Ethical permission was obtained from the research ethi-
cal committee for this study. A database of 652 patients
from 21 UK haematology centres was established and
maintained prospectively, as previously reported[18]. We
approached the question of the clinical significance of
changes in LVEF by determining the number of patients
recorded in the database who had: a) at least 2 cardio-
vascular magnetic resonance (CMR) scans; b) LVEF
measured by CMR at each time point and a baseline EF
of <71%, which is the lower half of the normal range for
thalassaemia major patients without cardiac iron load-
ing;[19] c) complete clinical follow-up for the clinical
outcome of heart failure for 12 months after each scan.
Patients on all treatments and all baseline cardiac T2*
values were included. The patient demographics are
shown in table 1. The primary outcome measure for
this study was the development of symptomatic heart
failure within 12 months of a CMR scan. A new diagno-
sis of heart failure was made only if the patient com-
plained of worsening dyspnoea at rest or during
exercise, objective LV dysfunction was present with an
ejection fraction of <56%,[1,9] and the caring clinician
made the clinical diagnosis of heart failure.
Patients were scanned with a 1.5T scanner (Sonata,
Siemens Medical Solutions, Erlangen, Germany) using
previously reported techniques[20]. In brief, CMR was
performed with a cardiac gated, single breath-hold, 8-
echo sequence (2.6 to 16.7 ms, increasing in 2.02-ms
increments) of a single mid-ventricular short-axis slice.
Long-axis cines and a contiguous stack of short-axis
cines were also acquired to assess left ventricular
dimensions and function using standard techniques
[21]. Data analysis was performed using CMRtools and
its plug-in Thalassemia-Tools (Cardiovascular Imaging
Solutions, London, UK) for the heart T2* (a large
region of the interventricular septum excluding regions
in proximity to the coronary veins), as well as left ven-
tricular ejection fraction using semi-automated plani-
metry of endocardial borders[21]. All scans were
reported at the time of acquisition by multiple opera-
tors, and a clinical report was generated for the refer-
ring physician.
Statistics
All statistical analyses were performed by a medical sta-
tistician. Two categories of baseline EF were used in this
analysis; 56-62% and 63-70%. These strata were used
because 63% is the lower limit of normal for EF in tha-
lassemia patients in the absence of myocardial siderosis,
[19] and 56% is the lower limit of normal for EF in nor-
mal subjects,[21] and patients with EF below this are
considered to have definite LV systolic dysfunction or
heart failure. Patients were eligible for inclusion in either
analysis provided they had one scan with an EF value
within the range of either category. All subsequent
scans for that patient were then analysed to assess the
i m p a c to ft h ec h a n g ei nE Fo nt h eo u t c o m e so fh e a r t
failure. Since only the first scan in a series for each
patient was required to be in the specified range, it is
possible for patients to be included in both sets of ana-
lyses. The association between changes in EF (for each
scan after the baseline scan, the change is calculated as
t h ed i f f e r e n c eb e t w e e nt h ec u r r e n ts c a na n dt h e
Table 1 Demographics of the patients at the first
qualifying scan for analysis.
Baseline ejection fraction group 56%-62% 63%-70%
N 109 216
Age 26.6 (8.6) 26.6 (8.7)
Sex
Male N (%) 59 (54.1) 110 (53.4)
Female N (%) 50 (45.9) 96 (46.6)
Ethnicity
Indian N (%) 31 (28.4) 56 (27.2)
Greek N (%) 18 (16.5) 31 (15.1)
Cypriot N (%) 17 (15.6) 30 (14.6)
Pakistani/Bangladeshi N (%) 14 (12.8) 32 (14.8)
Turkish/Arabic N (%) 12 (11.0) 18 (8.3)
Italian/Romanian N (%) 6 (5.5) 12 (5.6)
Chinese/Malay N (%) 5 (4.6) 4 (2.0)
Unknown N (%) 7 (6.4) 20 (9.3)
Ferritin [ug/L] 2140 (1600) 2065 (1636)
Cardiac T2* [ms] 19.7 (13.3) 23.2 (13.8)
Liver T2* [ms] 4.5 (4.3) 5.1 (4.6)
LVEDV [mL] 132.1 (33.5) 128.3 (38.4)
LVESV [mL] 49.3 (19.9) 43.8 (19.0)
LVEF [%] 59.7 (1.8) 66.7 (2.3)
Treatment
DFO N (%) 72 (66.1) 109 (52.9)
DFP N (%) 10 (9.2) 35 (17.0)
DFX N (%) 3 (2.75) 6 (2.9)
DFO + DFP N (%) 22 (20.2) 50 (24.3)
DFO + DFX N (%) 1 (0.9) 0 (0)
None N (%) 1 (0.9) 6 (2.9)
shown as mean (SD) except where N (%) is shown
LV-left ventricle, EDV-end-diastolic volume, ESV-end-systolic volume, EF-
ejection fraction, DFO-deferoxamine, DFP-deferiprone, DFX-deferasirox.
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effects Poisson regression model. Patients were entered
as random effects in the model (the random effects are
those things that we need to take account of, such as
the repeated measures within patients, but which we do
not want to estimate, for example we do not want to
compare individual patients to one another) with the
change in EF entered as a fixed effect (the fixed effect is
the predictor variable which we explicitly want to esti-
mate and quantify in terms of its association with the
outcome). A p-value of < 0.05 was taken to be signifi-
cant, and all analysis was performed using Stata 10.
Results
A total of 315 patients satisfied the selection inclusion
criteria, who had undergone 754 CMR scans. There
were 12 HF events in the 56-62% LVEF cohort and 14
in the 63-70% LVEF cohort. This equals an event rate of
11.0% and 6.8% respectively. Analysis of the occurrence
of heart failure showed a relative risk of 0.818 (p <
0.001) for the stratum of patients with baseline EF 56-
62%, which represents an 18.2% reduction in risk for
each 1% increase in EF (table 2). In the stratum of
patients with baseline EF of 63-70%, the relative risk
was 0.893 (p = 0.001), which represents a 10.7% reduc-
tion in risk for each 1% increase in EF. The incremental
effect of risk reduction associated with each 1% increase
in EF associated with drug treatment is illustrated in
Figure 1. The blue line shows the risk reduction for the
group with normal baseline EF, and the red line shows
the risk reduction for the group with low baseline EF.
The overall risk reduction associated with the improve-
ment in EF for 2 recent treatment trials is illustrated.
Discussion
Clinical trials of treatment frequently raise the challen-
ging question of whether a statistically significant
improvement in a trial endpoint is also clinically mean-
ingful. This can only be addressed by examining the
clinical outcomes associated with the improved end-
point, but trials are often designed for a technical out-
come of efficacy which may leave them underpowered
to directly derive the clinical meaningfulness. Such a
situation has arisen in the first randomized clinical trials
of oral iron chelation in cardiac siderosis of thalassemia
major, where the endpoint of LVEF was shown to be
significantly improved with treatment, but the sample
size in the trials of approximately 60 patients and the
period of follow-up were not sufficient to determine
clinical outcomes[8,9]. Under these circumstances an
alternative approach to the issue of assessing clinical sig-
nificance is required. We have approached this issue by
examining the clinical outcome of heart failure, with
reference to changes over time in EF, in a database of
TM patients which has sufficient size to answer out-
comes questions. Statistical modelling was applied to a
cohort of 315 patients who had at least 2 assessments of
LV EF by CMR to establish the relative risk for develop-
ment of heart failure within 12 months. In order to
address the issue of the significance of changes in EF for
patients whose baseline EF was in the normal range for
thalassemia major in the absence of cardiac siderosis
(>63%), we formed 2 strata for analysis related to nor-
mal ranges of EF, with baseline EF 56-62% (reduced EF
for TM patients) and 63-70% (lower half of the normal
range for TM patients). The results show that an
increase in LVEF is associated with statistically signifi-
cant risk reductions for heart failure for both strata of
baseline EF. For a 1% increase in EF, the risk reduction
for heart failure was 18.2% for the 56-62% EF stratum,
and 10.7% for the 63-70% stratum, both of which are of
substantial magnitude for such a small absolute change
in EF.
These results can then be applied to the findings in 2
comparative cardiac treatment randomized controlled
trials (Figure 1) which have been previously reported
that have used state of the art measurement of EF with
CMR, which is the most reproducible and accurate tech-
nique available[21-23]. For the deferiprone monotherapy
randomized controlled trial, a statistically significant
3.1% mean increase in EF was observed in the deferi-
prone arm[8]. The data from the current study indicate
that this degree of mean improvement in EF converts to
a mean reduction in risk for development of heart fail-
ure of 46.4% and 29.6% for patients with a baseline EF
of 56-62% and 63-70% respectively. For the combination
deferiprone-deferoxamine randomised controlled trial,
which showed a statistically significant EF increase of
2.6%,[9] the reduction in risk for development of heart
failure is 40.7% and 25.5% for patients with a baseline
EF of 56-62% and 63-70% respectively. The large magni-
tude of these risk reductions in heart failure indicate the
statistically significant findings from the randomized
controlled trials of deferiprone treatment are in addition,
clinically meaningful. The results also indicate that there
is a leftward shift in EF that occurs with cardiac iron
Table 2 Relative risk for development of heart failure for each 1% increase in ejection fraction (EF)
Baseline ejection fraction Relative risk 95% Confidence intervals p value Patients Scans
56-62% 0.818 0.767 0.872 <0.001 109 291
63-70% 0.893 0.836 0.953 0.001 206 463
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LV dysfunction can be present with EFs in the lower
normal range.
Although our analysis indicates significant clinical
benefit from the observed improvements in EF seen in
the randomized controlled trials of deferiprone, final
confirmation can only be obtained from clinical studies
comparing iron-induced cardiac morbidity and mortality
in transfusion-dependent patients treated with the chela-
tors for long periods of time. Randomized trials examin-
ing this question are not viable clinically, and the best
alternatives therefore are observational reports of the
long-term morbidity and mortality in association with
iron chelators. A literature search revealed 6 publica-
tions that compared morbidity and mortality in deferi-
prone-treated and deferoxamine-treated patients. All
studies reported significantly less morbidity and/or mor-
tality with deferiprone, but none showed less morbidity
or mortality in deferoxamine-treated patients[14,24-28].
Thus the predictions generated from the analyses in this
current study are consistent with the clinical outcomes
in large observational studies. The improved clinical
outcomes are also consistent with the finding of higher
EF with chronic deferiprone treatment compared with
deferoxamine treatment in a matched cohort study from
Anderson et al [29]. A further relevant study which is
consistent with the importance of the EF for cardiac
outcomes came from Davis et al, who studied 81 TM
patients with no history of heart disease with long-term
annual measurement of EF using radionuclide ventricu-
lography[30]. Cardiac death was significantly more com-
m o ni nt h ep a t i e n tc o h o r tw h o s eE Fw a s< 4 5 %o rw h o
sustained >10% absolute fall in EF between consecutive
measurements in comparison with patients whose EF
was >45% and who had <10% absolute fall in EF
between consecutive measurements. Although the abso-
lute threshold for abnormal EF is lower for methodolo-
gical reasons with the legacy radionuclide
ventriculography technique than for the now widely
available CMR method which was used in the current
study, [31] the data of Davis et al confirms the impor-
tance of the maintenance of the resting EF in TM, and
is in accord with the finding of the current study that a
rise of EF is associated with a lower risk of developing
heart failure.
Whilst the interpretation of these data indicates that
small improvements in EF are associated with meaning-
ful clinical benefits in outcomes, the mechanism of such
benefit has not been elucidated. The benefit cannot be
due to total body iron reduction, as deferiprone is no
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Figure 1 Reduction in risk of heart failure. Reduction in risk of heart failure shown for each 1% increase in ejection fraction for each baseline
ejection fraction stratum of patients (blue- normal baseline EF; red- low baseline EF). The risk reduction associated with the increases in ejection
fraction from 2 randomized controlled trials of deferiprone are shown, with the target drug doses[8,9]. The risk reductions associated with
improvements in EF of 2-3% are substantial and clinically meaningful in both groups.
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There are also no data to indicate that deferiprone has
any clinically significant inotropic or vasodilator effects,
and thus it is unlikely that clinical benefit accrues from
a primary effect on enhancing myocardial contractility
or changing dynamics of vascular flow. On the other
hand, the data do provide evidence of increased cardiac
performance, as measured by changes in LVEF. Thus it
is reasonable to consider mechanisms that might
enhance contractility in a heart that is beginning to fail
in patients with transfusional iron overload, and which
could be altered by the administration of an iron chela-
tor like deferiprone.
Considering possible mechanisms that might enhance
contractility in the failing heart of patients with transfu-
sional iron overload we can draw some analogies with
recent findings in Friedreich’s Ataxia, particularly the
association of cardiac abnormalities with excessive mito-
chondrial iron accumulation and their correction by
iron chelation [32]. We hypothesize that iron-mediated
damage of the heart, as reflected in LV function in iron
overload, is associated with heart cell mitochondria[33].
The endosymbiont mitochondria with their own DNA
are subcellular organelles which distinguish eukaryotic
from prokaryotic cells, and drive the cellular bioener-
getics responsible for the genomic complexity that has
permitted the evolution of multicellular organisms[34].
Mitochondria generate cellular energy in a biologically
useful form in the form of adenosine triphosphate
(ATP), and in the healthy human heart, mitochondria
harness more than 90% of cell ATP production via oxi-
dative phosphorylation[35]. In disease states such as
heart failure,[36] the mitochondrial oxidative capacity of
cardiac muscle cells may be diminished,[37-43] and con-
sequently the contractile performance of the failing
heart may be limited. In systemic iron overload, mito-
chondria are the major cellular sites of toxic iron accu-
mulation,[44] and it is therefore sensible to consider
mitochondrial “toxic iron” as a major pathophysiological
factor and an important target for iron chelation[45].
Evidence that heart failure in chronic iron overload may
be largely due to mitochondrial damage [46] was
obtained in mice injected with iron dextran over 4
weeks[47]. These animals showed various pathophysiolo-
gical changes due to chronic iron-induced organ toxi-
city, including cardiomyopathy: a) total cardiac iron was
increased almost 10-fold, which is similar in magnitude
to that reported at autopsy in hearts of TM patients
who had died of heart failure [2]; b) iron analysis
revealed approximately a 50% increase in extractable
(trichloroacetic acid-soluble) cardiac iron in iron-
injected animals; c) both biochemical and electron
microscopy analyses revealed extensive damage to
mitochondria in myocytes of iron-treated mice. The loss
of mitochondrial respiratory capacity and ensuing car-
diac dysfunction were attributed to decreased expression
of mitochondria encoded mRNA and proteins due to
mitochondrial DNA damage[47].
This leads to the question of why the heart is particu-
larly sensitive to excessive iron loading compared to
other tissues of polytransfused patients, which, in fact,
might accumulate even larger amounts of the metal.
The heart may be particularly sensitive to iron-induced
mitochondrial damage relative to other tissues because
of the large number of mitochondria which are required
for its high respiratory requirements, and its low level of
antioxidants[48]. Mitochondria generate ATP as a result
of the action of 5 respiratory chain complexes,[49] and
it has been estimated that the human heart creates 6 kg
of ATP daily for its metabolic needs[50,51]. In human
heart, deranged high energy phosphate metabolism is
detectable in heart failure and is a predictor of mortality
[52]. In rat heart cells, iron exposure reduced enzyme
complex activity by up to 65%, which resulted in
approximately a 25% drop in ATP production[49]. Con-
tractility is probably downregulated in response to the
reduced ATP production, and steady state ATP levels
are maintained until a more end-stage situation.
Respiratory chain inhibition could result from 4 main
mechanisms: First, iron exposure increases the genera-
tion of toxic reactive oxygen species (ROS),[53] espe-
cially hydroxyl radicals,[54] which can lead to
peroxidation of lipid components of the mitochondrial
membrane such as cardiolipin, and impairment of
respiratory chain complex assembly and activity;[55,56]
Second, peroxidation of polyunsaturated fatty acids can
lead to covalent protein linking which alters enzyme
activity;[57] Third, iron may bind directly to respiratory
chain enzymes and create active oxygen species which
convert amino acid residues to carbonyl derivatives that
reduce catalytic activity and increase protein degrada-
tion;[58] Fourth, ROS cause cumulative damage to mito-
chondrial DNA, reduced mitochondrial mRNA and
impaired synthesis of respiratory chain subunits coded
by the mitochondria, whereas subunits coded by nuclear
DNA are unaffected[33,47]. A vicious cycle may be cre-
ated where the respiratory chain enzymes may undergo
oxidative inactivation which may lead to incomplete
reduction of molecular oxygen and increased formation
of free radicals[59]. ROS and mitochondrial dysfunction
have also been linked to activation of the NLRP3
inflammasome, which is a molecular platform that trig-
gers innate immunity and pro-inflammatory cytokines
[60]. ROS also cause opening of the mitochondrial per-
meability transition pore, which can lead to cardiomyo-
cyte apoptosis [61,62]. These cellular and systemic
mechanisms associated with iron and redox
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rioration in cardiac function that occurs as a terminal
event in thalassemia major patients with heart failure.
Regardless of which of the above mechanisms is pri-
marily responsible for most of the iron-ROS evoked
damage in transfusional iron overload, improving EF
and meeting the high metabolic demands for increased
cardiac muscle contraction would depend on the ability
to restore mitochondrial activities and thereby improve
myocardial cell function. As increased cell labile iron
levels might play a key role in the pathophysiology of
heart failure,[63] a rational approach for treating cardiac
iron overload would entail reduction of intracellular
labile iron levels. An ideal iron chelating agent for this
would readily cross cellular and subcellular membranes,
and have an adequate affinity for specifically binding
labile iron while forming non-redox active iron com-
plexes that can also exit cells but also minimally inter-
fere with resident cell activities, particularly those that
are iron-dependent. Among the chelators in clinical use,
deferiprone was found to optimally meet the above cri-
teria in a frataxin-deficient HEK-293 cell model of mito-
chondrial iron accumulation [64]. Recent trials with
deferiprone on Friedriech’s ataxia patients indicate that
such a modus operandi might also be operative in the
clinical setting of hypertrophic cardiomyopathy observed
in these patients[32].
The three clinically available iron chelators, deferoxa-
mine, deferiprone and deferasirox all remove iron from
the body, but display different efficacy in removing
iron from different organs. Some of these differences
are attributable to their different chemical structures
that confer them with different chemical and physico-
chemical properties resulting in different bioavailabil-
ity, pharmacokinetics and tissue distribution including
accessibility to cellular labile iron pools [65-67]. The
small molecular weight bidentate deferiprone, com-
bined with its neutral charge and optimal partition
coefficient displays greater ability to permeate mem-
branes, [68,69] and remove iron from the myocardium
than the much larger, charged hexadentate deferoxa-
mine molecule[70]. The recently reported longitudinal
12 month trial of deferasirox in asymptomatic myocar-
dial siderosis also showed good cardiac iron removal,
but with an absence of improvement in LVEF,[11] with
both effects persisting to 2 years,[71] and 3 years[72].
These results were very similar to those found in the
US04 study[73,74].
Possible differences in the mode of action of deferi-
prone versus deferasirox might relate to a differential
drug accessibility to labile iron pools within cells (parti-
cularly within mitochondria) or with an intrinsic ability
of a chelator to associate with cell components such as
membranes or proteins and thereby become retained in
cells. Prolonged retention in cells can also be deleterious
as a chelator can interfere with the biosynthetic machin-
ery of heme or iron-S-clusters, and in extreme condi-
tions could drive cells into an apoptotic path[75-77]. On
the other hand, intermittent application of high doses of
deferasirox to aged animals on alternate days was not
only effective in reducing age related iron accumulation
but also iron-mediated cell apoptosis[78]. One can argue
that a relatively short time of tissue exposure to a chela-
tor might limit iron chelation efficacy in the organism.
However, relatively short exposures might also be
advantageous as possible interferences with essential
iron-dependent processes are also reduced. We propose
that this “kiss-and-go” modality of chelation might be
appropriate for removing iron that slowly accumulates
in particular cell compartments until reaching toxic
levels, as supported by basic and clinical data[64,79-81].
Further investigation of these possibilities is required to
explain the intriguing differences in ejection fraction
responses among the iron chelators. Whilst further basic
science studies will undoubtedly be helpful in this
mechanistic dissection, newer clinical trials may also
yield clues. For example, as clinical experience grows in
combining deferasirox with deferiprone for patient treat-
ment,[82] it would be interesting to identify whether
this combination is better, similar or worse at improving
LVEF in patients with stable chronic cardiac iron load-
ing than deferiprone in isolation.
Conclusion
Analysis of a large TM database showed that small
changes in ejection fraction have statistically significant
and clinically meaningful effects in reducing the
important clinical outcome of heart failure. These data
s u g g e s tt h a tt h er e s u l t sf r o mr a n d o m i z e dc o n t r o l l e d
trials using deferiprone in TM yield a 40.7% to 46.4%
relative risk reduction for heart failure in patients with
a baseline ejection fraction below normal of 56-62%,
and a 25.5% to 29.6% relative risk reduction for heart
failure in patients with normal baseline ejection frac-
tion of 63-70%. These predicted improved outcomes
are consistent with several reports of reduced heart
disease and increased survival in transfusion-dependent
patients treated with deferiprone, lending support to
the predictive value of improvement in clinical out-
come as a consequence of increasing LVEF. The data
indicate that prognostically important subclinical LV
dysfunction can occur in TM patients with cardiac
iron overload whilst EF remains in the lower normal
range. The most likely explanation for the improve-
ment in LV function found in the randomized con-
trolled trials using deferiprone, is improved myocardial
mitochondrial function although the exact mechanisms
remain to be fully elucidated.
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